This HTML5 document contains 313 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n27http://linked.opendata.cz/resource/AHFS/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00254/identifier/chemspider/
n9http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n28http://linked.opendata.cz/resource/drugbank/dosage/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00254/identifier/chebi/
n30http://www.drugs.com/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00254/identifier/wikipedia/
n17http://bio2rdf.org/drugbank:
n25http://linked.opendata.cz/resource/drugbank/drug/DB00254/identifier/pharmgkb/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00254/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n31http://www.rxlist.com/cgi/generic/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00254/identifier/bindingdb/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00254/identifier/pubchem-compound/
n16http://linked.opendata.cz/resource/drugbank/patent/
n15http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00254/identifier/pubchem-substance/
n13http://linked.opendata.cz/resource/drugbank/medicinal-product/
n8http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00254/identifier/drugbank/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00254/identifier/national-drug-code-directory/
n7http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00254
rdf:type
n3:Drug
n3:description
A synthetic tetracycline derivative with similar antimicrobial activity. Animal studies suggest that it may cause less tooth staining than other tetracyclines. It is used in some areas for the treatment of chloroquine-resistant falciparum malaria (malaria, falciparum). [PubChem]
n3:dosage
n28:271B404E-363D-11E5-9242-09173F13E4C5 n28:271B404F-363D-11E5-9242-09173F13E4C5 n28:271B4050-363D-11E5-9242-09173F13E4C5 n28:271B4051-363D-11E5-9242-09173F13E4C5 n28:271B404D-363D-11E5-9242-09173F13E4C5 n28:271B4056-363D-11E5-9242-09173F13E4C5 n28:271B4057-363D-11E5-9242-09173F13E4C5 n28:271B4058-363D-11E5-9242-09173F13E4C5 n28:271B4059-363D-11E5-9242-09173F13E4C5 n28:271B4052-363D-11E5-9242-09173F13E4C5 n28:271B4053-363D-11E5-9242-09173F13E4C5 n28:271B4054-363D-11E5-9242-09173F13E4C5 n28:271B4055-363D-11E5-9242-09173F13E4C5 n28:271B405E-363D-11E5-9242-09173F13E4C5 n28:271B405F-363D-11E5-9242-09173F13E4C5 n28:271B4060-363D-11E5-9242-09173F13E4C5 n28:271B4061-363D-11E5-9242-09173F13E4C5 n28:271B405A-363D-11E5-9242-09173F13E4C5 n28:271B405B-363D-11E5-9242-09173F13E4C5 n28:271B405C-363D-11E5-9242-09173F13E4C5 n28:271B405D-363D-11E5-9242-09173F13E4C5 n28:271B4066-363D-11E5-9242-09173F13E4C5 n28:271B4067-363D-11E5-9242-09173F13E4C5 n28:271B4068-363D-11E5-9242-09173F13E4C5 n28:271B4062-363D-11E5-9242-09173F13E4C5 n28:271B4063-363D-11E5-9242-09173F13E4C5 n28:271B4064-363D-11E5-9242-09173F13E4C5 n28:271B4065-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Dahl EL, Shock JL, Shenai BR, Gut J, DeRisi JL, Rosenthal PJ: Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother. 2006 Sep;50(9):3124-31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16940111 # Hoerauf A, Mand S, Fischer K, Kruppa T, Marfo-Debrekyei Y, Debrah AY, Pfarr KM, Adjei O, Buttner DW: Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Med Microbiol Immunol. 2003 Nov;192(4):211-6. Epub 2003 Mar 5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12684759 # Taylor MJ, Makunde WH, McGarry HF, Turner JD, Mand S, Hoerauf A: Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet. 2005 Jun 18-24;365(9477):2116-21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15964448
n3:group
approved investigational
n3:halfLife
18-22 hours
n3:indication
Doxycycline is indicated for use in respiratory tract infections caused by Mycoplasma pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae, Legionella spp., or Klebsiella spp. It is also used for prophylaxis of malaria. Doxycycline is indicated for a variety of bacterial infections, from Mycobacterium fortuitum and M. marinum, to susceptible E. coli and Brucella spp. It can be used as an alternative to treating plague, tetanus, Campylobacter fetus
n3:manufacturer
n4:271B4019-363D-11E5-9242-09173F13E4C5 n4:271B401A-363D-11E5-9242-09173F13E4C5 n4:271B4017-363D-11E5-9242-09173F13E4C5 n4:271B4018-363D-11E5-9242-09173F13E4C5 n4:271B401B-363D-11E5-9242-09173F13E4C5 n4:271B3FF9-363D-11E5-9242-09173F13E4C5 n4:271B3FFA-363D-11E5-9242-09173F13E4C5 n4:271B3FFD-363D-11E5-9242-09173F13E4C5 n4:271B3FFE-363D-11E5-9242-09173F13E4C5 n4:271B3FFB-363D-11E5-9242-09173F13E4C5 n4:271B3FFC-363D-11E5-9242-09173F13E4C5 n4:271B4001-363D-11E5-9242-09173F13E4C5 n4:271B4002-363D-11E5-9242-09173F13E4C5 n4:271B3FFF-363D-11E5-9242-09173F13E4C5 n4:271B4000-363D-11E5-9242-09173F13E4C5 n4:271B4005-363D-11E5-9242-09173F13E4C5 n4:271B4006-363D-11E5-9242-09173F13E4C5 n4:271B4003-363D-11E5-9242-09173F13E4C5 n4:271B4004-363D-11E5-9242-09173F13E4C5 n4:271B4009-363D-11E5-9242-09173F13E4C5 n4:271B400A-363D-11E5-9242-09173F13E4C5 n4:271B4007-363D-11E5-9242-09173F13E4C5 n4:271B4008-363D-11E5-9242-09173F13E4C5 n4:271B400D-363D-11E5-9242-09173F13E4C5 n4:271B400E-363D-11E5-9242-09173F13E4C5 n4:271B400B-363D-11E5-9242-09173F13E4C5 n4:271B400C-363D-11E5-9242-09173F13E4C5 n4:271B4011-363D-11E5-9242-09173F13E4C5 n4:271B4012-363D-11E5-9242-09173F13E4C5 n4:271B400F-363D-11E5-9242-09173F13E4C5 n4:271B4010-363D-11E5-9242-09173F13E4C5 n4:271B4015-363D-11E5-9242-09173F13E4C5 n4:271B4016-363D-11E5-9242-09173F13E4C5 n4:271B4013-363D-11E5-9242-09173F13E4C5 n4:271B4014-363D-11E5-9242-09173F13E4C5
owl:sameAs
n15:DB00254 n17:DB00254
dcterms:title
Doxycycline
adms:identifier
n12:Doxycycline n18:50845 n19:4444486 n20:50041429 n21:C06973 n22:49884-091-01 n23:DB00254 n24:46506491 n25:PA449415 n26:5281011
n3:mechanismOfAction
Doxycycline, like minocycline, is lipophilic and can pass through the lipid bilayer of bacteria. Doxycycline reversibly binds to the 30 S ribosomal subunits and possibly the 50S ribosomal subunit(s), blocking the binding of aminoacyl tRNA to the mRNA and inhibiting bacterial protein synthesis. Doxycycline prevents the normal function of the apicoplast of Plasmodium falciparum, a malaria causing organism.
n3:packager
n4:271B3FA2-363D-11E5-9242-09173F13E4C5 n4:271B3F9F-363D-11E5-9242-09173F13E4C5 n4:271B3FA0-363D-11E5-9242-09173F13E4C5 n4:271B3F9D-363D-11E5-9242-09173F13E4C5 n4:271B3F9E-363D-11E5-9242-09173F13E4C5 n4:271B3F9B-363D-11E5-9242-09173F13E4C5 n4:271B3F9C-363D-11E5-9242-09173F13E4C5 n4:271B3F99-363D-11E5-9242-09173F13E4C5 n4:271B3F9A-363D-11E5-9242-09173F13E4C5 n4:271B3F97-363D-11E5-9242-09173F13E4C5 n4:271B3F98-363D-11E5-9242-09173F13E4C5 n4:271B3FF7-363D-11E5-9242-09173F13E4C5 n4:271B3FF8-363D-11E5-9242-09173F13E4C5 n4:271B3FF5-363D-11E5-9242-09173F13E4C5 n4:271B3FF6-363D-11E5-9242-09173F13E4C5 n4:271B3FF3-363D-11E5-9242-09173F13E4C5 n4:271B3FF4-363D-11E5-9242-09173F13E4C5 n4:271B3FF1-363D-11E5-9242-09173F13E4C5 n4:271B3FF2-363D-11E5-9242-09173F13E4C5 n4:271B3FEF-363D-11E5-9242-09173F13E4C5 n4:271B3FF0-363D-11E5-9242-09173F13E4C5 n4:271B3FED-363D-11E5-9242-09173F13E4C5 n4:271B3FEE-363D-11E5-9242-09173F13E4C5 n4:271B3FEB-363D-11E5-9242-09173F13E4C5 n4:271B3FEC-363D-11E5-9242-09173F13E4C5 n4:271B3FE9-363D-11E5-9242-09173F13E4C5 n4:271B3FEA-363D-11E5-9242-09173F13E4C5 n4:271B3FE7-363D-11E5-9242-09173F13E4C5 n4:271B3FE8-363D-11E5-9242-09173F13E4C5 n4:271B3FE5-363D-11E5-9242-09173F13E4C5 n4:271B3FE6-363D-11E5-9242-09173F13E4C5 n4:271B3FE3-363D-11E5-9242-09173F13E4C5 n4:271B3FE4-363D-11E5-9242-09173F13E4C5 n4:271B3FE1-363D-11E5-9242-09173F13E4C5 n4:271B3FE2-363D-11E5-9242-09173F13E4C5 n4:271B3FDF-363D-11E5-9242-09173F13E4C5 n4:271B3FE0-363D-11E5-9242-09173F13E4C5 n4:271B3FDD-363D-11E5-9242-09173F13E4C5 n4:271B3FDE-363D-11E5-9242-09173F13E4C5 n4:271B3FDB-363D-11E5-9242-09173F13E4C5 n4:271B3FDC-363D-11E5-9242-09173F13E4C5 n4:271B3FD9-363D-11E5-9242-09173F13E4C5 n4:271B3FDA-363D-11E5-9242-09173F13E4C5 n4:271B3FD7-363D-11E5-9242-09173F13E4C5 n4:271B3FD8-363D-11E5-9242-09173F13E4C5 n4:271B3F95-363D-11E5-9242-09173F13E4C5 n4:271B3F96-363D-11E5-9242-09173F13E4C5 n4:271B3F93-363D-11E5-9242-09173F13E4C5 n4:271B3F94-363D-11E5-9242-09173F13E4C5 n4:271B3FD5-363D-11E5-9242-09173F13E4C5 n4:271B3FD6-363D-11E5-9242-09173F13E4C5 n4:271B3FD3-363D-11E5-9242-09173F13E4C5 n4:271B3FD4-363D-11E5-9242-09173F13E4C5 n4:271B3FD1-363D-11E5-9242-09173F13E4C5 n4:271B3FD2-363D-11E5-9242-09173F13E4C5 n4:271B3FCF-363D-11E5-9242-09173F13E4C5 n4:271B3FD0-363D-11E5-9242-09173F13E4C5 n4:271B3FCD-363D-11E5-9242-09173F13E4C5 n4:271B3FCE-363D-11E5-9242-09173F13E4C5 n4:271B3FCB-363D-11E5-9242-09173F13E4C5 n4:271B3FCC-363D-11E5-9242-09173F13E4C5 n4:271B3FC9-363D-11E5-9242-09173F13E4C5 n4:271B3FCA-363D-11E5-9242-09173F13E4C5 n4:271B3FC7-363D-11E5-9242-09173F13E4C5 n4:271B3FC8-363D-11E5-9242-09173F13E4C5 n4:271B3FC5-363D-11E5-9242-09173F13E4C5 n4:271B3FC6-363D-11E5-9242-09173F13E4C5 n4:271B3FC3-363D-11E5-9242-09173F13E4C5 n4:271B3FC4-363D-11E5-9242-09173F13E4C5 n4:271B3FC1-363D-11E5-9242-09173F13E4C5 n4:271B3FC2-363D-11E5-9242-09173F13E4C5 n4:271B3FBF-363D-11E5-9242-09173F13E4C5 n4:271B3FC0-363D-11E5-9242-09173F13E4C5 n4:271B3FBD-363D-11E5-9242-09173F13E4C5 n4:271B3FBE-363D-11E5-9242-09173F13E4C5 n4:271B3FBB-363D-11E5-9242-09173F13E4C5 n4:271B3FBC-363D-11E5-9242-09173F13E4C5 n4:271B3FB9-363D-11E5-9242-09173F13E4C5 n4:271B3FBA-363D-11E5-9242-09173F13E4C5 n4:271B3FB7-363D-11E5-9242-09173F13E4C5 n4:271B3FB8-363D-11E5-9242-09173F13E4C5 n4:271B3FB5-363D-11E5-9242-09173F13E4C5 n4:271B3FB6-363D-11E5-9242-09173F13E4C5 n4:271B3FB3-363D-11E5-9242-09173F13E4C5 n4:271B3FB4-363D-11E5-9242-09173F13E4C5 n4:271B3FB1-363D-11E5-9242-09173F13E4C5 n4:271B3FB2-363D-11E5-9242-09173F13E4C5 n4:271B3FAF-363D-11E5-9242-09173F13E4C5 n4:271B3FB0-363D-11E5-9242-09173F13E4C5 n4:271B3FAD-363D-11E5-9242-09173F13E4C5 n4:271B3FAE-363D-11E5-9242-09173F13E4C5 n4:271B3FAB-363D-11E5-9242-09173F13E4C5 n4:271B3FAC-363D-11E5-9242-09173F13E4C5 n4:271B3FA9-363D-11E5-9242-09173F13E4C5 n4:271B3FAA-363D-11E5-9242-09173F13E4C5 n4:271B3FA7-363D-11E5-9242-09173F13E4C5 n4:271B3FA8-363D-11E5-9242-09173F13E4C5 n4:271B3FA5-363D-11E5-9242-09173F13E4C5 n4:271B3FA6-363D-11E5-9242-09173F13E4C5 n4:271B3FA3-363D-11E5-9242-09173F13E4C5 n4:271B3FA4-363D-11E5-9242-09173F13E4C5 n4:271B3FA1-363D-11E5-9242-09173F13E4C5
n3:patent
n16:7749532 n16:5789395
n3:routeOfElimination
They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form.
n3:synonym
6-alpha-deoxy-5-oxytetracycline 5-Hydroxy-alpha-6-deoxytetracycline Supracyclin Jenacyclin 6α-deoxy-5-oxytetracycline (4S,4AR,5S,5ar,6R,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide 6alpha-Deoxy-5-oxytetracycline Vibramycin Doxiciclina Doxycycline (anhydrous) Doxycyclinum Doxycyclin
n3:toxicity
Symptoms of overdose include anorexia, nausea, diarrhoea, glossitis, dysphagia, enterocolitis and inflammatory lesions (with monilial overgrowth) in the anogenital region, skin reactions such as maculopapular and erythematous rashes, exfoliative dermatitis, photosensitivity, hypersensitivity reactions such as urticaria, angioneurotic oedema, anaphylaxis, anaphyl-actoid purpura, pericarditis, and exacerbation of systemic lupus erythematosus, benign intracranial hypertension in adults disappearing on discontinuation of the medicine, haematologic abnormalities such as haemolytic anaemia, thrombocytopenia, neutropenia, and eosinophilia. LD<sub>50</sub>=262 mg/kg (I.P. in rat).
n6:hasAHFSCode
n27:52-04-04 n27:08-12-24
n3:foodInteraction
Take with a full glass of water Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication. Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication. Avoid alcohol.
n3:proteinBinding
>90%
n3:salt
n3:synthesisReference
Dai-Wu Seol, "DNA cassette for the production of secretable recombinant trimeric TRAIL proteins, tetracycline/ doxycycline-inducible adeno-associated virus vector, their combination and use in gene therapy." U.S. Patent US20020128438, issued September 12, 2002.
n8:hasConcept
n9:M0006789
foaf:page
n30:doxycycline.html n31:doxycyc.htm
n3:IUPAC-Name
n5:271B406D-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B4073-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B4072-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B406F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B4070-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B4071-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B4083-363D-11E5-9242-09173F13E4C5 n5:271B406B-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B4085-363D-11E5-9242-09173F13E4C5 n5:271B406C-363D-11E5-9242-09173F13E4C5 n5:271B4069-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B406A-363D-11E5-9242-09173F13E4C5 n5:271B4086-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n7:A01AB22 n7:J01AA02
n3:H-Bond-Acceptor-Count
n5:271B4079-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B407A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B4074-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B4075-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B4077-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B4076-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B4078-363D-11E5-9242-09173F13E4C5
n3:absorption
Completely absorbed following oral administration.
n3:affectedOrganism
Brucella abortus Clostridium perfringens Enteric bacteria and other eubacteria Vibrio cholerae Treponema pallidum Borrelia burgdorferi Chlamydia psittaci Chlamydia trachomatis Rickettsia rickettsii Chlamydia pneumoniae Helicobacter pylori Brucella canis Neisseria gonorrhoeae Leptospira interrogans Mycoplasma pneumoniae Yersinia pestis
n3:casRegistryNumber
564-25-0
n3:category
n3:containedIn
n13:271B404B-363D-11E5-9242-09173F13E4C5 n13:271B404C-363D-11E5-9242-09173F13E4C5 n13:271B4049-363D-11E5-9242-09173F13E4C5 n13:271B404A-363D-11E5-9242-09173F13E4C5 n13:271B4047-363D-11E5-9242-09173F13E4C5 n13:271B4048-363D-11E5-9242-09173F13E4C5 n13:271B4045-363D-11E5-9242-09173F13E4C5 n13:271B4046-363D-11E5-9242-09173F13E4C5 n13:271B4043-363D-11E5-9242-09173F13E4C5 n13:271B4044-363D-11E5-9242-09173F13E4C5 n13:271B4041-363D-11E5-9242-09173F13E4C5 n13:271B4042-363D-11E5-9242-09173F13E4C5 n13:271B403F-363D-11E5-9242-09173F13E4C5 n13:271B4040-363D-11E5-9242-09173F13E4C5 n13:271B403D-363D-11E5-9242-09173F13E4C5 n13:271B403E-363D-11E5-9242-09173F13E4C5 n13:271B403B-363D-11E5-9242-09173F13E4C5 n13:271B403C-363D-11E5-9242-09173F13E4C5 n13:271B4039-363D-11E5-9242-09173F13E4C5 n13:271B403A-363D-11E5-9242-09173F13E4C5 n13:271B4037-363D-11E5-9242-09173F13E4C5 n13:271B4038-363D-11E5-9242-09173F13E4C5 n13:271B4035-363D-11E5-9242-09173F13E4C5 n13:271B4036-363D-11E5-9242-09173F13E4C5 n13:271B4033-363D-11E5-9242-09173F13E4C5 n13:271B4034-363D-11E5-9242-09173F13E4C5 n13:271B4031-363D-11E5-9242-09173F13E4C5 n13:271B4032-363D-11E5-9242-09173F13E4C5 n13:271B402F-363D-11E5-9242-09173F13E4C5 n13:271B4030-363D-11E5-9242-09173F13E4C5 n13:271B402D-363D-11E5-9242-09173F13E4C5 n13:271B402E-363D-11E5-9242-09173F13E4C5 n13:271B402B-363D-11E5-9242-09173F13E4C5 n13:271B402C-363D-11E5-9242-09173F13E4C5 n13:271B4029-363D-11E5-9242-09173F13E4C5 n13:271B402A-363D-11E5-9242-09173F13E4C5 n13:271B4027-363D-11E5-9242-09173F13E4C5 n13:271B4028-363D-11E5-9242-09173F13E4C5 n13:271B4025-363D-11E5-9242-09173F13E4C5 n13:271B4026-363D-11E5-9242-09173F13E4C5 n13:271B4023-363D-11E5-9242-09173F13E4C5 n13:271B4024-363D-11E5-9242-09173F13E4C5 n13:271B4021-363D-11E5-9242-09173F13E4C5 n13:271B4022-363D-11E5-9242-09173F13E4C5 n13:271B401F-363D-11E5-9242-09173F13E4C5 n13:271B4020-363D-11E5-9242-09173F13E4C5 n13:271B401D-363D-11E5-9242-09173F13E4C5 n13:271B401E-363D-11E5-9242-09173F13E4C5 n13:271B401C-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B407F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B4081-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B4082-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B4084-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B407E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B407D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B4080-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B406E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B407B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B407C-363D-11E5-9242-09173F13E4C5